Comorbid Moderate-Severe Depressive Symptoms and their Association with Quality of Life in Chinese Patients with Schizophrenia Treated in Primary Care.
This study described the prevalence and correlates of comorbid moderate-severe depressive symptoms (comorbid depression thereafter) and their association with quality of life (QOL) in schizophrenia patients treated in primary care. 623 schizophrenia patients were enrolled. Patients' socio-demographic and clinical characteristics including comorbid depression [defined as a total score of 18 or above on the Montgomery-Asberg Depression Rating Scale (MADRS)] were recorded. Depressive symptoms (defined as a total score of 9 or above on the MADRS) were present in 54.1 % of patients, while 17.7 % had comorbid depression. Analysis of covariance revealed that comorbid depression was significantly associated with lower mental QOL. Multiple logistic regression analysis revealed that more severe positive and negative symptoms, anxiety symptoms, use of first-generation antipsychotics and antidepressants, were independently associated with comorbid depression. Given the negative association between comorbid depression and QOL, attempts to address comorbid depression in schizophrenia patients treated in primary care should be made.
Guangdong Mental Health Center, Guangdong General Hospital, Guangdong Academy of Medical Sciences, Guangzhou, Guangdong, China.
Cai-Lan
CL
Hou
Ningxia Mental Health Center, Ningxia Ning-An Hospital, Yinchuan, Ningxia, China.
Xin-Rong
XR
Ma
Guangzhou Yuexiu Center for Disease Control and Prevention, Guangzhou, Guangdong, China.
Mei-Ying
MY
Cai
Mood Disorders Centre, Beijing Anding Hospital, Capital Medical University, Beijing, China.
Yan
Y
Li
Shenzhen Key Laboratory for Psychological Healthcare, Shenzhen Institute of Mental Health, Shenzhen Kangning Hospital, Shenzhen Mental Health Center, Shenzhen, China.
Yu
Y
Zang
Guangdong Mental Health Center, Guangdong General Hospital, Guangdong Academy of Medical Sciences, Guangzhou, Guangdong, China. jiafujun@126.com.
Fu-Jun
FJ
Jia
Guangdong Mental Health Center, Guangdong General Hospital, Guangdong Academy of Medical Sciences, Guangzhou, Guangdong, China.
Yong-Qiang
YQ
Lin
Department of Psychiatry, Chinese University of Hong Kong, Hong Kong SAR, China.
Helen F K
HF
Chiu
School of Psychiatry and Clinical Neurosciences, University of Western Australia, Perth, Australia.|Marian Centre, The University of Notre Dame Australia, Perth, Australia.
Gabor S
GS
Ungvari
Department of Psychology, University of Macau, Macao SAR, China.
Brian J
BJ
Hall
Department of Psychiatry, Chinese University of Hong Kong, Hong Kong SAR, China.
Bao-Liang
BL
Zhong
Shenzhen Key Laboratory for Psychological Healthcare, Shenzhen Institute of Mental Health, Shenzhen Kangning Hospital, Shenzhen Mental Health Center, Shenzhen, China.
Xiao-Lan
XL
Cao
Unit of Psychiatry, Faculty of Health Sciences, University of Macau, Avenida da Universidade, 3/F, Building E12, Macau SAR, Taipa, China. xyutly@gmail.com.
Yu-Tao
YT
Xiang
D000328:Adult; D000928:Antidepressive Agents / Q000627:therapeutic use; D014150:Antipsychotic Agents / Q000627:therapeutic use; D044466:Asian People / Q000523:psychology*; D002681:China / Q000453:epidemiology; D015897:Comorbidity; D003430:Cross-Sectional Studies; D003866:Depressive Disorder / Q000453:epidemiology*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D011320:Primary Health Care; D011788:Quality of Life; D012559:Schizophrenia / Q000453:epidemiology*; D011795:Surveys and Questionnaires
D000928:Antidepressive Agents; D014150:Antipsychotic Agents
China; Community-dwelling; Depressive symptoms; Primary care; Schizophrenia